ATG presents epitope-mapping advance to DECHEMA Peptide Symposium


ATG presents epitope-mapping advance to DECHEMA Peptide Symposium


ATG Logo
MycoSync Logo
EU Logo

Press Release | ATG:biosynthetics GmbH

MARCH 06, 2017

Merzhausen, Germany: – German-based pre-clinical contract research organization ATG:biosynthetics (ATG) will present details of its advanced new Epitope Mapping Service to the 13th DECHEMA German Peptide Symposium in Erlangen.

Dr. Adrien Eberlin, Project Manager and Lab Manager in ATG’s R&D Department will represent the company at the conference at University Clinic of Erlangen.

On Day Three of the event, Wednesday March 22, Dr. Eberlin will deliver a lecture on ‘PepID-focused BioDesign of peptides for epitope-mapping microarrays in vaccine development by genome analysis’ to the session on Peptides in Immunology.

He will describe ATG’s novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology. The new methodology aims to maximize the efficacy of multi-epitope vaccines.

MycoSynVac origins

“We believe our peers at the Peptide Symposium will be very interested to hear about this powerful new research tool,” said Dr. Eberlin.

“We are now bringing epitope-mapping to market and will be communicating more intensively on this advanced ATG service during the course of 2017,” said Dr. Eberlin.

ATG initially developed its peptide library for epitope mapping to support 2013 and 2014 research projects aiming to identify origins and human antibody responses to the West Nile Virus (WNV).

Subsequently, as part of the MycoSynVac consortium, ATG has developed a new workflow that drastically reduces the number of peptides to test in compiling an optimal list.

Bioinformatic prediction

When combined with powerful PepID computational algorithms, these allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.

The presentation will also acknowledge the contribution of Dr. Josef Maier of Information Services to Life Science (IStLS) as a co-developer of the new epitope mapping tool.

Reducing complexity

“The new workflow reduces the complexity of the library while conserving the biodiversity of the peptides,” commented ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, who played a leading role in developing the new library design system.

“Such reduction of complexity considerably reduce the cost and time of global epitope mapping project including the entire surfome of the pathogen to be targeted,” Dr. Bernauer explained.

About ATG: biosynthetics

ATG :biosynthetics is a German-based pre-clinical contract research company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway engineering) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About German Peptide Symposium 2017

The German Peptide Symposium is an annual event that covers all areas of peptide science, including peptide chemistry, biochemistry, biophysics, structural biology, immunology, pharmacology, as well as the use of proteins and peptides in medicine and material sciences.

The 13th Annual Symposium is a four-day event opening March 20 at the Friedrich-Alexander University Clinic of Erlangen, near Nuremberg in South Eastern Germany.

The event is organized by DECHEMA e.V. (Society for Chemical Engineering and Biotechnology), a non-profit professional society of almost 6,000 members.

DECHEMA brings together experts from a wide range of disciplines, institutions and generations to stimulate scientific exchange in chemical engineering, process engineering and biotechnology to represent these fields in science, industry, politics and society.

More information at: http://dechema.de/en/peptide13_2017.html

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

OR

Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0)7423-8772786

Resources

Click on ATG at German Peptide Symposium for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Comments are closed.